Soror Tamer, Kovács György, Seibold Nina, Melchert Corinna, Baumann Kristin, Wenzel Eike, Stojanovic-Rundic Suzana
Interdisciplinary Brachytherapy Unit, University of Luebeck/UKSH-CL, Ratzeburger Allee 160, 23538, Luebeck, Germany.
National Cancer Institute (NCI), Radiation Oncology Department, Cairo University, Cairo, Egypt.
Strahlenther Onkol. 2017 May;193(5):367-374. doi: 10.1007/s00066-016-1093-6. Epub 2017 Jan 2.
Patients with early-stage breast cancer can benefit from adjuvant accelerated partial breast irradiation (APBI) following breast-conserving surgery (BCS). This work reports on cosmetic results following APBI using multicatheter high-dose-rate interstitial brachytherapy (HDR-IBT).
Between 2006 and 2014, 114 patients received adjuvant APBI using multicatheter HDR-IBT. For each patient, two photographs were analyzed: the first was taken after surgery (baseline image) and the second at the last follow-up visit. Cosmesis was assessed by a multigender multidisciplinary team using the Harvard Breast Cosmesis Scale. Dose-volume histogram (DVH) parameters and the observed cosmetic results were investigated for potential correlations.
The median follow-up period was 3.5 years (range 0.6-8.5 years). The final cosmetic scores were 30% excellent, 52% good, 14.5% fair, and 3.5% poor. Comparing the baseline and follow-up photographs, 59.6% of patients had the same score, 36% had a better final score, and 4.4% had a worse final score. Only lower target dose nonuniformity ratio (DNR) values (0.3 vs. 0.26; p = 0.009) were significantly associated with improved cosmetic outcome vs. same/worse cosmesis.
APBI using multicatheter HDR-IBT adjuvant to BCS results in favorable final cosmesis. Deterioration in breast cosmesis occurs in less than 5% of patients. The final breast cosmetic outcome in patients treated with BCS and APBI using multicatheter HDR-IBT is influenced primarily by the cosmetic result of the surgery. A lower DNR value is significantly associated with a better cosmetic outcome.
早期乳腺癌患者在保乳手术(BCS)后可从辅助性加速部分乳腺照射(APBI)中获益。本文报道了使用多导管高剂量率组织间近距离放疗(HDR-IBT)进行APBI后的美容效果。
2006年至2014年间,114例患者接受了使用多导管HDR-IBT的辅助性APBI。对每位患者分析两张照片:第一张在手术后拍摄(基线图像),第二张在最后一次随访时拍摄。由多性别多学科团队使用哈佛乳腺美容量表评估美容效果。研究剂量体积直方图(DVH)参数与观察到的美容效果之间的潜在相关性。
中位随访期为3.5年(范围0.6 - 8.5年)。最终美容评分优秀者占30%,良好者占52%,中等者占14.5%,差者占3.5%。比较基线照片和随访照片,59.6%的患者评分相同,36%的患者最终评分更好,4.4%的患者最终评分更差。与美容效果相同/更差相比,仅较低的靶区剂量不均匀率(DNR)值(0.3对0.26;p = 0.009)与改善的美容结局显著相关。
BCS辅助使用多导管HDR-IBT进行APBI可带来良好的最终美容效果。不到5%的患者出现乳腺美容恶化。接受BCS和使用多导管HDR-IBT进行APBI治疗的患者的最终乳腺美容结局主要受手术美容效果影响。较低的DNR值与更好的美容结局显著相关。